Physician profile
Lawrence M Stein
NPI 1043203359
$2,768.15
in general payments reported to CMS, 2019-2025
31 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $78.67 · 2021: $111 · 2022: $772 · 2023: $451 · 2024: $605 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,536.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,063.24 | 2019-2025 | Inspire |
| Glaxosmithkline, LLC. | $228.27 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Insmed, INC. | $137.48 | 2020-2024 | Arikayce |
| 3b Medical, INC. | $128.92 | 2024-2025 | Luna |
| Axsome Therapeutics, INC. | $101.94 | 2023-2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.38 | 2019-2023 | Spiriva Respimat, Ofev |
| Shionogi INC | $98.60 | 2024-2025 | Fetroja |
| Novartis Pharmaceuticals Corporation | $97.62 | 2023-2024 | |
| Mylan Specialty L.P. | $80.64 | 2022-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $61.99 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $59.67 | 2022-2023 | Airsupra |
| United Therapeutics Corporation | $59.45 | 2023 | Tyvaso |
| Zoll Respicardia, INC. | $54.97 | 2023-2024 | Remede System |
| Abbvie INC. | $51.98 | 2023-2024 | Avycaz |
| Harmony Biosciences LLC | $41.69 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $41.65 | 2019-2021 | |
| Allergan, INC. | $40.00 | 2019 | |
| Genzyme Corporation | $38.15 | 2021 | |
| Monaghan Medical Corporation | $31.12 | 2024 | Aerobika |
| Vapotherm INC | $26.30 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.05 | 2025 | Glassia |
| Biogen, INC. | $24.43 | 2025 | Spinraza |
| Amgen INC. | $23.67 | 2024 | Tezspire |
| Avadel Cns Pharmaceuticals, LLC | $23.12 | 2024 | Lumryz |
| Vanda Pharmaceuticals INC. | $22.44 | 2020 | |
| Alexion Pharmaceuticals, INC. | $20.41 | 2024 | Ultomiris |
| Pfizer INC. | $17.62 | 2025 | |
| Idorsia Pharmaceuticals US INC | $17.57 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $17.39 | 2024 | Xarelto |
| Advanced Respiratory, INC | $15.42 | 2020 | |
| Lilly USA, LLC | $14.97 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.